Enzalutamide: An evidence-based review of its usein the treatment of prostate cancer

Keyphrases

• Prostate Cancer 100%
• Enzalutamide 100%
• Evidence-based Review 100%
• Androgen Receptor 45%
• Metastatic Castration-resistant Prostate Cancer (mCRPC) 27%
• Phase I Study 18%
• Castration-resistant Prostate Cancer 18%
• Chemotherapy 18%
• Docetaxel 9%
• Phase II Trial 9%
• Placebo 9%
• Seizure 9%
• Headache 9%
• Overexpression 9%
• Novel Therapies 9%
• Prostate Cancer Patients 9%
• Safety Profile 9%
• Clinical Utility 9%
• Androgen Receptor Antagonist 9%
• Overall Survival 9%
• Adverse Events 9%
• Nave 9%
• Disease Stage 9%
• MEDLINE 9%
• Peer-reviewed Articles 9%
• Median Overall Survival 9%
• Optimal Combination 9%
• Androgen Response Element 9%
• Hot Flashes 9%
• Place in Therapy 9%
• Evidence Review 9%
• Trial Testing 9%
• Optimal Sequencing 9%
• Gene Promoter Region 9%

Pharmacology, Toxicology and Pharmaceutical Science

• Enzalutamide 100%
• Prostate Cancer 100%
• Androgen Receptor 54%
• Castration Resistant Prostate Cancer 45%
• Chemotherapy Regimens 18%
• Overall Survival 18%
• Placebo 9%
• Docetaxel 9%
• Headache 9%
• Adverse Event 9%
• Hot Flush 9%
• Phase III and IV Trials 9%
• Androgen 9%
• Diseases 9%